Medical Devices & Surgical Technology Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Devices & Surgical Technology Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Asthma
Pharmaxis reports Phase III results for Aridol as asthma test
December 24th, 2006
Pharmaceutical company Pharmaxis (PXS, PXSL) announced the results from its U.S.-based Phase III trial for Aridol as a diagnostic test for asthma. The trial was conducted in 30 U.S. centers in more than 500 patients under an U.S. Food & Drug Administration approved protocol who were suspected of having asthma but who did not have a firm diagnosis. In this group with predominantly very mild symptoms, Aridol was able to identify patients with exercise-induced bronchoconstriction in 58% of cases (sensitivity). In comparison methacholine, an approved lung function test in the U.S., identified 54% of cases. The difference between the two tests was not...
Source: Medical Devices & Surgical Technology Week (2006-12-24)
|
